Restriction enzyme market seen climbing to $1.67B by 2030

The global restriction enzyme market is projected to grow from $1.04 billion in 2025 to $1.15 billion in 2026, then reach $1.67 billion by 2030. Growth is being driven by genomics, personalized medicine, and expanding biotech research demand across academic, clinical, and industrial users.

Why it matters: - Restriction enzymes are core tools for DNA cutting, cloning, sequencing, and genome mapping. - Rising demand signals more activity in genomics, diagnostics, and genetic engineering across research and biotech markets. - The market’s expected move from $1.04 billion in 2025 to $1.67 billion by 2030 points to sustained spending on molecular biology tools.

What happened: - The Business Research Company released its Restriction Enzyme Global Market Report 2026, covering market size, trends, and a forecast through 2035. - The report says the market will grow from $1.04 billion in 2025 to $1.15 billion in 2026. - The report projects the market will reach $1.67 billion by 2030, at a 9.9% CAGR. - The release was dated Sept. 23, 2026, from London. - A free sample report is available here. - The full report is available here.

The details: - The report ties market growth to breakthroughs in molecular biology research. - Expanded use of recombinant DNA technology is supporting demand. - Broader genomics work in academic and clinical settings is adding volume. - Biotech research and development funding is increasing enzyme use. - Demand for cloning and sequencing tools is another growth driver. - Restriction enzymes recognize specific DNA sequences and cut DNA at or near those sites. - The enzymes are used for gene cloning, genome mapping, recombinant DNA technology, and precise DNA manipulation. - Controlled biotechnological manufacturing is used to preserve high specificity, consistent activity, and reliability. - The report says large-scale genomics projects are a major market driver. - Governments and institutions are increasing investment in genomic research to improve disease diagnosis and advance precision medicine. - In 2024, the NHS Genomic Medicine Service in England performed more than 810,000 genomic tests, up 8% from the prior year. - Personalized medicine is another key catalyst for demand. - The FDA approved 16 new personalized treatments for rare diseases in 2023, compared with six in 2022. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Between the lines: - The forecast suggests restriction enzymes remain a foundational input for next-generation genetic research, even as newer platforms expand. - The strongest demand appears tied to precision medicine and scaling genomics programs, not just basic research. - Regional growth outside North America likely reflects broader adoption of genetic testing and biotech infrastructure.

What's next: - The market is expected to keep expanding as genomics testing and personalized medicine programs grow. - The report’s 2030 forecast implies continued need for cloning, sequencing, and DNA engineering tools. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, hotspot infographics, and updated graphics and tables. - The company lists Saumya Sahay as an expert contact for follow-up questions.